- Home
- CXDO vs PBYI Comparison
CXDO vs PBYI Comparison
Compare CXDO & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CXDO | PBYI |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 263.4M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | CXDO | PBYI |
|---|---|---|
| Price | $7.45 | $6.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.13 | $7.00 |
| AVG Volume (30 Days) | 115.0K | ★ 378.2K |
| Earning Date | 03-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 201.70 | 59.87 |
| EPS | 0.14 | ★ 0.74 |
| Revenue | $66,346,000.00 | ★ $211,995,000.00 |
| Revenue This Year | $14.40 | N/A |
| Revenue Next Year | $11.52 | N/A |
| P/E Ratio | $51.97 | ★ $9.26 |
| Revenue Growth | ★ 12.91 | N/A |
| 52 Week Low | $3.75 | $2.58 |
| 52 Week High | $7.65 | $6.90 |
Technical Indicators
Market Signals| Indicator | CXDO | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 63.93 | 71.90 |
| Support Level | $6.90 | $6.29 |
| Resistance Level | $7.49 | $6.29 |
| Average True Range (ATR) | 0.28 | 0.28 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 77.54 | 75.56 |
Price Performance
Historical ComparisonAbout CXDO Crexendo Inc.
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.